Poly Medicure Limited , a leading medical devices manufacturer, has announced its financial results for the second quarter, showcasing modest growth in both revenue and profitability.

Financial Highlights

The company reported a consolidated net profit of ₹918.30 million for Q2, representing a 5% increase from ₹874.50 million in the same period last year. This growth in profitability comes alongside a 5.7% year-over-year increase in revenue, which rose to ₹4.44 billion from ₹4.20 billion.

Key Performance Metrics

While Poly Medicure maintained its EBITDA at ₹1.15 billion, the EBITDA margin saw a decline of 158 basis points, dropping to 25.84% from 27.42% in the previous year. This suggests that while the company has managed to grow its top line and bottom line, it has faced some pressure on operational efficiency.

Management Commentary

The company's board of directors reviewed and approved these unaudited consolidated financial results at their meeting. The results have also undergone a limited review by the statutory auditors, who expressed an unmodified review report on both standalone and consolidated financial statements.

Business Developments

During the quarter, Poly Medicure made significant strides in expanding its global footprint:

1. The company acquired a 90% economic interest in the Pendra Care Group through its subsidiary, RISOR Holding BV. This acquisition includes Pendra Care Holdings BV and Welling Medical BV, potentially enhancing Poly Medicure's presence in the European market.

2. Poly Medicure has been approved as a resolution applicant for Himalayan Mineral Water Private Limited by the National Company Law Tribunal (NCLT) of Allahabad. The company has deposited ₹3,316 million for this acquisition, which is pending final formalities.

3. The company continued its employee stock option scheme, allotting 33,775 equity shares at a face value of ₹5 each, with an exercise price of ₹100 per share.

Market Segment and Future Outlook

Poly Medicure continues to operate primarily in the medical devices segment, which remains its sole reportable segment. The company's strategic acquisitions and expansions suggest a focus on strengthening its position in both domestic and international markets.

While the company has shown resilience with growth in revenue and profit, the slight decline in EBITDA margin may warrant attention in the coming quarters. Investors and stakeholders will likely be watching how Poly Medicure leverages its recent acquisitions to drive future growth and operational efficiencies.

The unaudited results for the quarter and half-year are available on the company's website ( www.polymedicure.com ) and on the stock exchange websites ( www.nseindia.com and www.bseindia.com ) for further details.

Poly Medicure Limited , a prominent player in the medical devices industry, has announced the completion of a significant acquisition through its wholly-owned subsidiary, Poly Medicure B.V. Amsterdam, Netherlands. The company has successfully acquired full ownership of Medistream SA, a Swiss corporation, along with its subsidiaries, collectively known as the Citieffe Group.

Acquisition Details

The acquisition, which was initially disclosed on September 24, 2025, has now been finalized as of November 6, 2025. This strategic move gives Poly Medicure 100% economic and voting rights in the Citieffe Group, marking a significant expansion of its global footprint.

Citieffe Group: New Step-down Subsidiaries

As a result of this acquisition, Poly Medicure has added several new step-down subsidiaries to its corporate structure:

Regulatory Compliance

The company has affirmed that all closing conditions stipulated in the Share Purchase Agreement (SPA) have been fulfilled. This transaction complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and adheres to the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Strategic Implications

This acquisition represents a significant step for Poly Medicure in expanding its international presence. By gaining full control of the Citieffe Group, the company has potentially enhanced its product portfolio, market reach, and technological capabilities in the medical devices sector.

While specific financial details of the transaction were not disclosed in the available information, this move is likely to strengthen Poly Medicure's position in the global medical devices market, particularly in Europe and the Americas, given the locations of the newly acquired subsidiaries.

As the medical devices industry continues to evolve, such strategic acquisitions may play a crucial role in companies' growth strategies and their ability to compete on a global scale.